Neurocrine Biosciences | NBIX - Pre Tax Profit

Stock Price
129.71
Daily Change
-1.93 -1.47%
Monthly
0.13%
Yearly
42.74%
Q2 Forecast
127.64

Neurocrine Biosciences reported $239.4M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Agios Pharmaceuticals USD -109.06M 5.62M Dec/2025
ALKERMES USD 100.74M 4.1M Sep/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Amgen USD 3.92B 2.35B Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Exelixis USD 252.69M 275K Dec/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Incyte USD 389.94M 92.37M Dec/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Pfizer USD 3.33B 290M Sep/2025
Prothena USD -21.58M 15.33M Dec/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Repligen USD 17.11M 10.25M Sep/2025
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Teva Pharmaceutical Industries USD 91M 555M Dec/2025
Ultragenyx Pharmaceutical USD -128M 51.54M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025
Xoma USD 15.98M 24.58M Jun/2024